BioNTech SE (BNTX) Free Cash Flow Growth (3y) (2021 - 2026)
Powered by 
Analysis
BioNTech SE (BNTX) Free Cash Flow Growth (3y) (2021 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -1.95% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -20.15% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 21.16% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 45.09% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 80.69% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -4.45% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 8.92% |
| 10 | BioNTech SE | 25.06 Bn | 11.41 Bn | 10.00 Mn | -75.01% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -75.01% |
| Mar 31, 2026 | 14.35% |
| Dec 31, 2025 | -23.92% |
| Sep 30, 2025 | -42.02% |
| Jun 30, 2025 | -64.13% |
| Mar 31, 2025 | -29.42% |
| Dec 31, 2024 | -52.57% |
| Sep 30, 2024 | -32.61% |
| Jun 30, 2024 | 129.94% |
| Mar 31, 2024 | -39.25% |
| Dec 31, 2023 | 45.38% |
| Sep 30, 2023 | 61.15% |
| Jun 30, 2023 | 557.37% |
| Mar 31, 2023 | -129.43% |
| Dec 31, 2022 | 61.62% |
| Sep 30, 2022 | 347.16% |
| Jun 30, 2022 | 311.25% |
| Mar 31, 2022 | 375.87% |
| Dec 31, 2021 | 63.26% |